[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"gastro-intestinal-cancer\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:gastro-intestinal-cancer":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,42],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":27,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":30,"lastUpdatePostDateStruct":31,"startDateStruct":34,"completionDateStruct":36,"leadSponsor":38,"locationsCount":41},"100464769","phase-2-sfolfoxiri-in-advanced-gastroesophageal-cancer-sage-100464769",false,"NCT05332002","sFOLFOXIRI in Advanced Gastroesophageal Cancer, (SAGE)","A Phase II Study of sFOLFOXIRI in Advanced Gastroesophageal Cancer (SAGE)","Inclusion Criteria:\n\n* Histologically and\u002For cytologically confirmed metastatic or unresectable adenocarcinoma of esophageal, gastroesophageal junction or gastric origin\n* Tumor is HER2 negative by standard local testing methodology\n* Eastern Cooperative Oncology Group Performance Status (ECOG PS) of 0 - 2\n* Measurable disease by response evaluation criteria in solid tumors (RECIST) v1.1\n* No prior systemic therapy for the present cancer given in the metastatic setting and \\> 6 months from administration of peri-operative chemotherapy, if applicable\n\n  o Note: up to two prior cycles of mFOLFOX6 for the present illness is permitted if patients otherwise qualify for the study with adequate baseline imaging\n* At least 18 years of age\n* Adequate bone marrow and organ functions as defined by:\n* Absolute neutrophil count ≥ 1500 cells\u002F μL\n* Hemoglobin ≥ 8 g\u002F dL\n* Platelets \\> 100,000 \u002F μL\n* Creatinine ≤ 1.5 x upper limit of normal (ULN) OR creatinine clearance ≥ 30 mL\u002Fmin by Cockroft-Gault\n* Total bilirubin ≤ ULN\n* Aspartate aminotransferase (AST)\u002F Alanine aminotransferase (ALT) \\\u003C 2.5 x ULN, unless with liver metastases and then must be \\\u003C5 x ULN of normal\n* Women and men of childbearing potential must agree to use adequate contraception (hormonal or barrier method of birth control or abstinence) prior to study entry and for the duration of study participation. Should a woman become pregnant or suspect pregnancy on study, she must notify her treating physician immediately.\n* Ability to understand the nature of this study protocol and give written informed consent.\n* Willingness and ability to comply with scheduled visits, treatment plans laboratory tests and other study procedures.\n\nExclusion Criteria:\n\n* Receipt of any investigational agents at the time of registration\n* Known, untreated brain metastases\n* Grade two or greater peripheral neuropathy\n* Presence of any additional active malignancy within the past three years where the malignancy is at least reasonably likely to later the course of therapy, require systemic therapy or interfere with imaging assessments\n* For those patients who are going to receive nivolumab\n* No active use of systemic corticosteroids at the time of enrollment, at a dose equivalent of 10 mg\u002Fday or prednisone\n* Clinically significant autoimmune disease which is active or has required systemic immunosuppression within the last two years\n* Prior organ transplant or bone marrow transplant\n* History of interstitial lung disease or pneumonitis\n* Uncontrolled intercurrent illness, including significant active infection, symptomatic congestive heart failure, unstable angina or active arrhythmia\n* Major surgery within the four weeks prior to initiation of study treatment\n* A history of allergy or hypersensitivity to any of the study drugs\n* Any additional significant medical condition, laboratory abnormality, or psychiatric illness that would prevent the subject from fully participating in the study","ALL","18 Years",{"count":19,"type":20},38,"ESTIMATED","INTERVENTIONAL",[23],"PHASE2","The primary objective is to determine the clinical efficacy of treatment regimen in terms of objective response rate (ORR). The secondary objectives is to determine the clinical efficacy of the study treatment in terms of progression free survival (PFS) and overall survival (OS). Additionally, to characterize the safety and toxicity profile of the study treatment as measured by the adverse event rates.",[26],"Gastro-Intestinal Cancer",[28],"Gastric and esophageal cancers (GEC)","RECRUITING","2026-01-05",{"date":32,"type":33},"2026-01-07","ACTUAL",{"date":35,"type":33},"2022-07-13",{"date":37,"type":20},"2026-08-01",{"name":39,"class":40},"Rutgers, The State University of New Jersey","OTHER",6,{"id":43,"slug":44,"hasResults":11,"nctId":45,"briefTitle":46,"officialTitle":47,"acronym":4,"eligibilityCriteria":48,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":49,"targetDuration":4,"studyType":21,"phases":51,"briefSummary":53,"conditions":54,"keywords":68,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":79,"lastUpdatePostDateStruct":80,"startDateStruct":82,"completionDateStruct":84,"leadSponsor":86,"locationsCount":88},"100580294","high-resolution-pet-ct-specimen-imaging-for-the-perioperative-visualization-of-resection-margins-100580294","NCT06835426","High-resolution PET-CT Specimen Imaging for the Perioperative Visualization of Resection Margins","High-resolution PET-CT Specimen Imaging for the Perioperative Visualization of Resection Margins: an Exploratory Pilot Study","A. Inclusion Criteria:\n\n* able to understand treatment protocol and informed consent form\n* estimated by the investigator to be compliant for study participation\n\n  1\\. Fulfilling all group-specific inclusion criteria:\n* confirmed breast cancer with an indication to undergo breast conserving surgery\n* confirmed prostate cancer with an indication to undergo resective surgeryprostatectomy;\n* confirmed thyroid lesion with an indication to undergo resective surgery;\n* confirmed parathyroid adenoma with an indication to undergo resective surgery;\n* suspected basal cell carcinoma, squamous cell carcinoma or melanoma with an indication to undergo resective surgery;\n* suspected lesion in genitourinary sites (including bladder cancer, renal pelvis and ureter carcinoma, adrenal cortical carcinoma and renal cell carcinoma) with an indication to undergo resective surgery;\n* suspected lesion in the head \\& neck region with an indication to undergo resective surgery;\n* confirmed primary or secondary hepatobiliary cancer with an indication to undergo resective surgery;\n* patients undergoing biopsy after metabolic active lesions were detected on a PET scan.\n* suspected neuro-endocrine malignancies with an indication to undergo resective surgery.\n* suspected brain tumor with an indication to undergo resective surgery.\n* Suspected malignant and benign gastrointestinal lesions with an indication to undergo resective surgery.\n* suspected malignant thoracovascular lesions with an indication to undergo resective surgery\n\nB. Exclusion Criteria:\n\n* general or local contra-indications for resective surgery;\n* in case of FDG-based PET tracers: a blood glucose level over 200 mg\u002FdL on the day of surgery;\n* pregnancy or lactation;\n* participation in other clinical studies with a radiation exposure of more than 1 mSv in the past year.",{"count":50,"type":20},150,[52],"NA","These are patients in whom a benign or malignant tumor was recorded requiring surgery. During that surgery, the surgeon will cut away the tumor as part of the treatment of the disease. In this process, it is important that the tumor is removed correctly and completely. To verify that the correct tissue was completely removed, the tissue is examined microscopically. However, a microscopic analysis takes a relatively long time and the result is not known until a few days after the surgery is completed. If that microscopic analysis should eventually reveal that the tumor was not completely removed, additional treatment is usually necessary. An assessment of the excised tissue during surgery would allow additional tissue to be excised in the same operation if necessary. Thus, in this way, additional treatments can also be avoided. This could lead to shorter treatment time and less emotional strain for the patient, as well as lower costs. To date, however, there are no effective techniques to do this.\n\nPositronEmissionTomography (PET) imaging can be used to image the tumor that needs to be excised. To do this, a tracer must be administered through the blood before the operation. This tracer is a slightly radioactive substance that can be detected by the PET camera even at low concentrations. This technique is already routinely used in the hospital to detect cancer or inflammatory tissue in the body. During this study, however, it's not the intention to look at the tumor while it is still in the patient's body, but rather after it has been cut out of the patient's body by the surgeon. To do this, the piece of tissue cut away will be scanned using a specially designed PET-CT scanner.\n\nThe overall goal of this study is to gain additional knowledge. More specifically, the investigators wish to determine which medical conditions may benefit from high-resolution PET-CT specimen imaging.",[55,56,57,58,59,60,61,62,63,64,65,66,67],"Breast Carcinoma","Prostate Cancer Surgery","Thyroid Cancer","Parathyroid Adenomas","Skin Cancer","Genitourinary Cancer","Head and Neck Cancer","Hepatobiliary Cancers","Metabolic Abnormality","Neuro Endocrine Tumours","Brain Tumours","Gastro Intestinal Cancer","Thoracoscopic Surgery",[69,70,71,72,73,74,75,76,77,78],"resective surgery","perioperative high-resolution PET-CT specimen imaging","breast cancer","Prostate cancer","thyroid cancer","parathyroid cancer","head and neck cancer","neuro-endocrine malignancies","genitourinary malignacies","thoracovascular malignancies","2025-02-14",{"date":81,"type":33},"2025-02-19",{"date":83,"type":33},"2023-08-06",{"date":85,"type":20},"2027-06-30",{"name":87,"class":40},"Algemeen Ziekenhuis Maria Middelares",1]